Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03824067
Other study ID # EG0170
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 1, 2017
Est. completion date October 31, 2019

Study information

Verified date December 2019
Source Elizabeth Glaser Pediatric AIDS Foundation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This mixed methods study will utilize a randomized step-wedge design to assess the impact of point-of-care (POC) versus conventional early infant diagnosis (EID) on key outcomes including timely return of results to caregivers and time to initiation on treatment for HIV-infected infants. Data will be collected through longitudinal clinical follow-up and medical chart extraction of routine records and lab forms. Feasibility and acceptability data will be collected through interviews with mothers/caregivers of HIV-exposed infants, and community focus groups.


Description:

This study seeks to evaluate the impact of point of care (POC) early infant HIV diagnosis (EID) on turn-around time from sample collection until notification of parents/caregivers of test result, linkage to care, and time to initiation of treatment, and early retention in HIV care (3-6 months) for those infected. The study will take place in two countries, Zimbabwe and Kenya, with high HIV prevalence, and where EGPAF-supported POC EID platforms are being implemented as part of a Unitaid-funded POC EID project. As part of POC program implementation activities, in each country up to 50 EGPAF-supported sites will implement POC EID platforms. These sites may be prevention of mother-to-child transmission (PMTCT) of HIV clinics, HIV clinics or multidisciplinary health facilities. Project sites have been selected as part of the program implementation. In each country, 18 sites will be randomly selected as study sites for the impact evaluation. Using a stepped wedge design, the intervention (the POC EID platforms) will be rolled out sequentially to the study facilities over three randomly-assigned time periods. Quantitative data will be derived from routine medical and laboratory charts and longitudinal tracking and follow-up of HIV-infected infants. Qualitative data on feasibility and acceptability of POC will be derived from in-depth interviews with mothers/caregivers of HIV-exposed infants at the beginning and end of the study and community focus group discussions at the end of the study.


Recruitment information / eligibility

Status Completed
Enrollment 9539
Est. completion date October 31, 2019
Est. primary completion date October 30, 2019
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Any infant who receives an EID test, either conventional or POC, for the 4-6 week EID indication at one of the study sites (which were randomly selected from project sites in country) - HEI under 12 weeks of age or their parents/caregivers - Some methods will only include HEI who test positive (medical chart extraction and longitudinal follow up) - Purposively selected caregivers of HEI for in-depth interviews - Focus groups with community members will not require participants to have sought testing for EID Exclusion Criteria: - Participants not at selected study sites - For some methods (medical chart extraction and longitudinal follow-up), HEI who test negative - For qualitative component, excluded if unable to consent due to age, competence, or inability to speak any of the study languages

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Point of Care Early Infant Diagnosis
HIV testing where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
Standard of Care Early Infant Diagnosis
Conventional laboratory based EID testing

Locations

Country Name City State
Kenya Elizabeth Glaser Pediatric AIDS Foundation Nairobi
Zimbabwe Elizabeth Glaser Pediatric AIDS Foundation Harare

Sponsors (2)

Lead Sponsor Collaborator
Elizabeth Glaser Pediatric AIDS Foundation UNITAID

Countries where clinical trial is conducted

Kenya,  Zimbabwe, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of HIV exposed infants (HEI) who have received the 4-6 week EID test result by 12 weeks The number of children for whom a sample was drawn for the 4-6-week indication receiving EID result by 12 weeks, divided by the number of HEI who presented to the clinic and had an indication for 4-6 week EID testing 12 weeks
Secondary Testing coverage for the 4-6 week indication Number of EID samples collected for 4-6 week indication divided by the number of HEI who presented to the clinic and had an indication for 4-6 week EID testing 18 months
Secondary Time from sample collection for 4-6 week EID test indication to parent's/ caregiver notification Date of sample collection to the date that results were given to care giver 18 months
Secondary Age of patient at test result notification for 4-6 week EID test indication HEIs date of birth, date of sample collection and date of result notification to care giver 18 months
Secondary Time from test result received for 4-6 week EID test to initiation of ART, for HIV-infected infants Date positive result received at facility to the date the result was communicated to mother and date of ART initiation 18 months
Secondary Percentage of HIV positive infants diagnosed during 4-6 week EID testing initiated on ART Number of HIV-infected infants initiated on ART after 4-6 week EID test divided by the number of HIV-infected infants identified after 4-6 week EID test 18 months
Secondary Number of HIV-infected infants diagnosed at the 4-6 week EID with retention in care at 6 months Total number of infants initiated on ART 6 months ago and number of active on ART at 6 months 24 months
See also
  Status Clinical Trial Phase
Completed NCT03413696 - Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
Completed NCT03215901 - Life Plans Intervention Study N/A
Completed NCT03289676 - Storytelling Narrative Communication Intervention for Smoking Cessation in Women Living With HIV Phase 1
Completed NCT03268551 - MEMO-Medical Marijuana and Opioids Study
Active, not recruiting NCT04064567 - Linking High-Risk Jail Detainees to HIV Pre-Exposure Prophylaxis: PrEP-LINK N/A
Completed NCT04013295 - Prize-linked Savings Initiatives for Promoting Better Health and Economic Outcomes in Kenya N/A
Recruiting NCT04405700 - Measuring Adverse Pregnancy and Newborn Congenital Outcomes
Recruiting NCT03984136 - HIV Results Exchange Mechanism on Promoting HIV Testing Among MSM N/A
Completed NCT02928900 - Patient Actor Training to Improve HIV Services for Adolescents in Kenya N/A
Recruiting NCT03268109 - COGnitive ImpairmenT in Older HIV-infected Patients ≥ 65 Years Old
Completed NCT02797262 - Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System N/A
Completed NCT02376582 - Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS Phase 1
Completed NCT01957865 - Real-Time Antiretroviral Therapy Adherence Intervention in Uganda N/A
Completed NCT01616940 - Minority AIDS Initiative Retention and Re-Engagement Project N/A
Terminated NCT01443923 - Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV Phase 4
Completed NCT01910714 - Adapting and Evaluating an EBI to Prevent HIV/AIDS Risk Among Apache Youth N/A
Completed NCT01084421 - A Computer-Based Parent/Adolescent HIV Communication Intervention for Latinos N/A
Completed NCT01596322 - International HIV Antiretroviral Adherence, Resistance and Survival N/A
Completed NCT03643705 - A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention N/A
Completed NCT03923231 - Pharmacokinetics of Atazanavir in Special Populations